Physician profile
Casey E Larue
NPI 1104025105
$14,395.12
in general payments reported to CMS, 2019-2025
54 companies · $2,703 in 2025
The $2,703 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,253 · 2022: $2,869 · 2023: $3,075 · 2024: $2,495 · 2025: $2,703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,272.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,585.77 | 2021-2025 | |
| Pfizer INC. | $1,475.27 | 2021-2025 | |
| Lilly USA, LLC | $1,436.86 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,228.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $902.64 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $750.17 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $745.87 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $584.91 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $472.59 | 2021-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $442.41 | 2021-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.88 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $401.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $347.49 | 2021-2025 | |
| Esperion Therapeutics, INC. | $309.87 | 2021-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Larue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.